Reading this on a mobile device? Try our optimized mobile version here:

January 24, 2013
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • Zevalin works as initial therapy for follicular non-Hodgkin lymphoma
    Initial treatment with the radioimmunotherapy Zevalin, also called 90-yttrium ibritumomab tiuxetan, allowed 35% of 59 patients with follicular non-Hodgkin lymphoma to have long-lasting responses, according to a study published in the Journal of Clinical Oncology. Patients' overall response rate at six months was 86%, and 41% of patients showed complete response. "In our opinion, radioimmunotherapy is a particularly attractive therapy for older patients, patients with significant comorbidity, or patients who refuse chemotherapy," researchers said. Medscape (free registration) (1/22) LinkedInFacebookTwitterEmail this Story
Finally, a practical way to personalize PET doses.
The MEDRAD™ Intego™ PET Infusion System utilizes a fully shielded, mobile design with integrated dosimetry to enable clinicians to determine and administer an accurate, personalized dose for each patient. To see how the MEDRAD™ Intego™ is supporting better patient care, click here.
  Clinical News & Research 
  • Study: Hyperbaric treatment has potential to treat stroke patients
    Researchers exploring the potential of hyperbaric oxygen therapy in restoring neurological function in brain tissue of post-stroke patients found the method increased neuronal activity at two months post-treatment. Improvements include paralysis reversal, renewed language use and better sensation, according to the study published in PLoS ONE. Researchers used CT imaging to detect necrotic tissue and SPECT scans to measure metabolic activity in neurons surrounding damaged areas. Researchers are also exploring the method for traumatic brain injury. release (1/23) , HealthDay News (1/23) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Bo pharma to distribute Verisante's Aura system in more countries
    Canadian company Verisante has entered into an extended exclusive deal with Dutch firm bo pharma BV involving the distribution of Verisante's Aura optical system, used in detecting and diagnosing skin lesions, in a number of European countries. The Aura technology employs Raman spectroscopy to noninvasively assess skin lesions suspected as cancerous prior to biopsy. BioOptics World (1/23) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  International Developments 
  Health Policy 
  Advancing Health Care 
  • VCs invested $907 million in mobile health last year
    After a strong first six months in 2012, venture capitalists' mobile health investments fell in the final two quarters of the year, according to Mobile Health Market News, which pegged total 2012 spending at $907.7 million with a 6% decline in the fourth quarter compared with the previous period. Health IT accounted for the greatest share of investments, followed by health care monitoring. Healthcare IT News (1/22) LinkedInFacebookTwitterEmail this Story
  From SNMMI 
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

All news is an exaggeration of life."
--Daniel Schorr,
American journalist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Account Director:   Meryl Harold   (202) 407-7828
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information